Clik here to view.
The Pharma Four: Similar ETFs, Different Returns (PPH, XPH, IHE, PJP, XLV)
Jared Cummans: Pharmaceutical companies have long been popular investments as they offer relatively inelastic products as well as strong dividend yields that give both growth and value investors...
View ArticleClik here to view.
Bright Spots In The ETF Landscape: Five Funds Holding Their Value In A Wild...
Michael Johnston: So far, this year has been tough for markets around the globe. Since the downgrade of U.S. credit quality in August, equity markets have become plagued with rampant volatility,...
View ArticleClik here to view.
New Global Big Pharma ETN Hits The Market (DRGS, IHE, PJP, XPH, PPH)
Michael Johnston: RBS rolled out its fifth ETN this week, debuting a product that offers exposure to the world’s largest pharmaceutical firms. The new Global Big Pharma ETN (NYSE:DRGS) will seek to...
View ArticleClik here to view.
The 5 Best ETFs Over The Past 5 Years (IAU, SLV, FBT, TLT, PJP, SPY)
Eric Dutram: In the last five years, investors have witnessed a variety of market conditions. Stocks were relatively strong in the middle part of 2007 but, as we all know, proceeded to fall apart...
View ArticleClik here to view.
What Patent Cliff? Pharmaceutical ETFs Continue To Surge (PJP, XPH, IHE, JNJ,...
Eric Dutram: For at least the past few years, investors in the health care segment have been focused in on big pharma and the segment’s fast approaching ‘patent cliff’. During this period, many of the...
View ArticleClik here to view.
Three ETFs With Surprisingly Stellar 3-Year Returns (THD, RTL, REZ, PJP)
Daniela Pylypczak: For the most part, many people would agree that investing can sometimes be a crapshoot. Investors often find themselves playing a game of musical chairs, shifting their assets to...
View ArticleClik here to view.
Balchunas on the Rally in Some Pharmaceutical ETFs (IHE, XPH, PJP)
Bloomberg ETF analyst Eric Balchunas discusses the rally in three exchange-traded funds that focus on the pharmaceutical industry. Bloomberg Radio’s Catherine Cowdery reports on Exchange Traded Funds....
View ArticleClik here to view.
3 Best (And 3 Worst) ETF Performers Over The Last 3 Years (THD, PJP, SIVR,...
Carolyn Pairitz: This past year has been marked by uncertainty, but nothing compared to recent years, prompting investors to return in droves from safe haven accounts to the U.S. stock market....
View ArticleClik here to view.
Investor Guide To Four Pharmaceutical ETFs
The pharmaceutical industry has been showing signs of recovery from one of the biggest patent cliffs in recent times. Although genericization will continue, the major patent expiries are over and done...
View ArticleClik here to view.
Why Investors Should Consider Pharmaceutical ETFs
The healthcare space, no doubt, is one of the leading sectors this year courtesy of the incredible performances by major drug companies in both pharmaceutical and biotechnology industries. While the...
View ArticleClik here to view.
How To Play The Bullish Trend In Healthcare With ETFs
While there have been a series of volatility-inducing events in the U.S. starting from the Fed’s ‘Taper Talk’ and then the tussle between the Republicans and the Democrats, investors have still...
View ArticleClik here to view.
3 Pharmaceutical ETFs Leading The Healthcare Sector
The pharmaceutical industry has been performing remarkably well this year after emerging relatively unscathed from one of the biggest patent cliffs in recent times. Thanks goes largely to robust...
View ArticleClik here to view.
ETFs Which Look To Benefit From The Affordable Care Act
The Affordable Care Act—often known as Obamacare—has faced an incredible amount of scrutiny over the past few years. First, the law was fought in Congress, then in the court system, and it had to...
View ArticleClik here to view.
Quick Investor Guide To Pharmaceutical ETFs
With the year coming to an end, the worst of the patent cliff faced by the pharmaceutical sector in recent times is over. Although genericization will continue, the major patent expiries are over and...
View ArticleClik here to view.
Top Pharmaceutical ETFs To Consider
After the incredible surge in 2013, the healthcare sector is no doubt crushing the overall market this year too. This is largely thanks to the bullish trend in both the pharma and biotech segments and...
View ArticleClik here to view.
ETFs To Watch As Obamacare Hits Deadline
Despite the rocky start and a plethora of technical issues, the Affordable Care Act (often known as Obamacare) saw a surge in enrollment in the final days of its first year program. More than 6 million...
View ArticleClik here to view.
ETFs To Cash In On Aging Global Population
Neena Mishra: Global population is growing older at an unprecedented rate. The number of persons aged 60 years or more worldwide is expected to increase from 841 million in 2013 to more than 2 billion...
View ArticleClik here to view.
ETFs To Watch On Strong Earnings From Pharma Companies
The pharma space has been seeing smooth trading thanks to encouraging industry trends such as development of new drugs, the rising wave of mergers and acquisitions, increased need for medical services,...
View ArticleClik here to view.
ETF Impact On Biotech Earnings
The Q2 earnings season has so far been great for biotech companies with most of them giving solid quarterly updates. Biotech giant Gilead Sciences (GILD) continued with its exceptional performance in...
View ArticleClik here to view.
A Beaten-Up Pharma With a Big Upside
The Medicines Company(NASDAQ:MDCO) has had a really tough first half of 2014, and the stock price shows it. When one of its drugs did not receive approval from regulators and a court decision...
View Article
